Clinical trial
EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study
NCT00216255 · Endo Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00216255 |
|---|---|
| Title | EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study |
| Official title | An 8-week, Double-blind, Randomized, Multicenter, Flexible-dose, Placebo Controlled Pilot Study of Pagoclone in Patients With PDS Followed by a 52-week Open-label Extension |
| Lead sponsor | Endo Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Persistent Developmental Stuttering |
| Intervention type | Drug |
| Interventions | Pagoclone, Placebo |
| Enrollment | 120 |
| Start date | Apr 1, 2005 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 3, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: